You just read:

Acurx Receives USAN Approval of Non-proprietary Name Ibezapolstat for Its Phase 2 Novel, First-in-Class Antibiotic for C. difficile Infection

News provided by

Acurx Pharmaceuticals, LLC

Jan 15, 2020, 08:00 ET